Condition: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · CLL Variant · Sponsor: Zulfa Omer
This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This description comes directly from the study's public registry record.
UCCC Clinical Trials Office · 513-584-7698 · cancer@uchealth.com
Zulfa Omer, MD · cancer@uchealth.com
Always discuss trial participation with your own doctor first.
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07014917